Advertisement

 

 

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.

Tobacco Harm Reduction with Vaporised Nicotine (THRiVe): The Study Protocol of an Uncontrolled Feasibility Study of Novel Nicotine Replacement Products among People Living with HIV Who Smoke.
Author Information (click to view)

Bell S, Dean J, Gilks C, Boyd MA, Fitzgerald L, Mutch A, Baker P, Neilsen G, Gartner CE,


Bell S, Dean J, Gilks C, Boyd MA, Fitzgerald L, Mutch A, Baker P, Neilsen G, Gartner CE, (click to view)

Bell S, Dean J, Gilks C, Boyd MA, Fitzgerald L, Mutch A, Baker P, Neilsen G, Gartner CE,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

International journal of environmental research and public health 2017 07 1814(7) pii 10.3390/ijerph14070799

Abstract

Smoking is a leading cause of morbidity and premature mortality among people living with HIV (PLHIV), who have high rates of tobacco smoking. Vaporised nicotine products (VNPs) are growing in popularity as a quit aid and harm reduction tool. However, little is known about their acceptability and use among PLHIV. Using a pragmatic, uncontrolled, mixed methods design this exploratory clinical trial aims to examine the feasibility of conducting a powered randomised clinical trial of VNPs as a smoking cessation and harm reduction intervention among vulnerable populations, such as PLHIV who smoke tobacco. Convenience sampling and snowball methods will be used to recruit participants (N = 30) who will receive two VNPs and up to 12 weeks’ supply of nicotine e-liquid to use in a quit attempt. Surveys will be completed at weeks 0 (baseline), 4, 8, 12 (end of treatment) and 24 (end of the study) and qualitative interviews at weeks 0 and 12. As far as we are aware, this feasibility study is the first to trial VNPs among PLHIV for smoking cessation. If feasible and effective, this intervention could offer a new approach to reducing the high burden of tobacco-related disease among PLHIV and other vulnerable populations.

Submit a Comment

Your email address will not be published. Required fields are marked *

4 × one =

[ HIDE/SHOW ]